Document is current
Any future updates will be listed below
-
Authors
Vivarelli, Marina https://orcid.org/0000-0002-2448-1959
van de Kar, Nicole https://orcid.org/0000-0002-1990-1189
Labbadia, Raffaella
Diomedi-Camassei, Francesca
Thurman, Joshua M. https://orcid.org/0000-0002-3476-9956
- License Information
-
More Information
Article History
Received: 24 January 2021
Revised: 28 March 2021
Accepted: 20 April 2021
First Online: 18 May 2021
Declarations
:
: MV received funding from the Associazione per la cura del Bambino Nefropatico ONLUS and has served on advisory boards for Novartis, Apellis, Roche, Achillion, Retrophin and participated in the C3G clinical trials by Chemocentrix and Achillion. NK is member of the advisory board of Roche and participant in the clinical trials in C3G by Chemocentryx and Achillion. RL and FD: no funding or conflict of interest to report. JMT receives royalties from Alexion Pharmaceuticals, Inc. and is a consultant for Q32 Bio, Inc., a company developing complement inhibitors. He also holds stock and will receive royalty income from Q32 Bio, Inc. This does not influence the content of this manuscript.
